Sixteen patients who were receiving placebo received sunitinib at the time of disease progression , with the best responses being 1 partial response ( 6.3 % ) , 6 cases of stable disease ( 37.5 % ) , and 5 cases of progressive disease ( 31.3 % ) ; 4 patients were not evaluable for response .